Neurosense, Health Canada discuss approval path for PrimeC

Last summer, a large limb on our old mountain ash died, and this spring, our teenage son cut it off, leaving only one limb coming out of the stump of a once beautiful tree. “Is it time to take it down?” I asked my husband, Todd. “I think so,” he…

Researchers using a fish model of amyotrophic lateral sclerosis (ALS) found that damage to the cerebellum — a brain region not traditionally associated with ALS — begins before motor symptoms emerge. This damage appears to be driven by reduced levels of PAICS, an enzyme involved in the production of…

A team at Stanford University has received a $13 million grant to uncover previously unknown genetic causes of amyotrophic lateral sclerosis (ALS), with the goal of identifying targets for future treatments. The grant, awarded by the California Institute for Regenerative Medicine (CIRM) to a team led by Stanford…

The statistical methods scientists use to analyze outcomes from clinical trials in amyotrophic lateral sclerosis (ALS) vary widely, and these differences may make some trials prone to generating misleading results, a study found. The researchers focused on analysis of the ALS Functional…

Two leaders at Brainstorm Cell Therapeutics, which is developing the experimental cell-based therapy NurOwn (debamestrocel) for people with amyotrophic lateral sclerosis (ALS), have published a paper calling on the U.S. Food and Drug Administration (FDA) to modernize its review process for experimental therapies for ALS and other…

Several nonprofits are uniting to fund new research aimed at identifying targets for the treatment of amyotrophic lateral sclerosis (ALS). The new initiative will be led by the Allen Institute, a nonprofit medical research organization, through its Brain Health Accelerator — a research initiative to study neurodegenerative diseases. The…

My husband, Todd, and I just finished watching the TV series “Person of Interest,” about a type of super artificial intelligence (AI) that predicts crime. The series, which ran from 2011 to 2016, was prescient about current issues resulting from AI and mass surveillance. In the penultimate episode, one of…

PAS-004, an experimental therapy that Pasithea Therapeutics is developing to address inflammation and TDP-43 protein clumps, has received orphan drug designation by the U.S. Food and Drug Administration for the treatment of amyotrophic lateral sclerosis (ALS). The status aims to accelerate the development of therapies for rare diseases, or…

I am always looking for ways to simplify my life and help my days go by a bit more smoothly. But when you live with ALS, like I do, there is always one extra thing to do, plan, or think about before you can even begin an activity. It’s…